SD4 Stock Overview Focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Spectral Medical Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Spectral Medical Historical stock prices Current Share Price CA$0.35 52 Week High CA$0.47 52 Week Low CA$0.26 Beta 0.95 1 Month Change 1.15% 3 Month Change -1.68% 1 Year Change 9.32% 3 Year Change 96.65% 5 Year Change -36.00% Change since IPO 70.05%
Recent News & Updates
Spectral Medical Provides November Tigris Trial Update Dec 03
Third quarter 2024 earnings released: CA$0.035 loss per share (vs CA$0.012 loss in 3Q 2023) Nov 10
Spectral Medical Inc. Provides October Tigris Trial Update Nov 05
Spectral Medical Inc. Provides September Tigris Trial Update Oct 04
New minor risk - Insider selling Sep 19
Independent Chairman of the Board recently sold €65k worth of stock Sep 18 See more updates
Spectral Medical Provides November Tigris Trial Update Dec 03
Third quarter 2024 earnings released: CA$0.035 loss per share (vs CA$0.012 loss in 3Q 2023) Nov 10
Spectral Medical Inc. Provides October Tigris Trial Update Nov 05
Spectral Medical Inc. Provides September Tigris Trial Update Oct 04
New minor risk - Insider selling Sep 19
Independent Chairman of the Board recently sold €65k worth of stock Sep 18
Spectral Medical Inc. Provides August Tigris Trial Update Sep 04
Second quarter 2024 earnings released: CA$0.016 loss per share (vs CA$0.014 loss in 2Q 2023) Aug 11
Spectral Medical Inc Provides July Tigris Trial Update Aug 02 Spectral Medical Inc. announced that it has received $1 million in funding Jul 24
Spectral Medical Inc. announced that it expects to receive $1 million in funding Jul 23
Spectral Medical Inc. Provides June Tigris Trial Update Jul 03 Spectral Medical Inc. announced that it has received CAD 8.499564 million in funding May 31
First quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.006 loss in 1Q 2023) May 13 Spectral Medical Inc. announced that it expects to receive CAD 8.499564 million in funding May 10
Spectral Medical Inc. Provides Tigris Trial Update May 08
Spectral Medical Provides Tigris Trial Update Apr 11
Less than half of directors are independent Apr 05
Spectral Medical Inc. Announces Board Changes Apr 02
Full year 2023 earnings released: CA$0.056 loss per share (vs CA$0.028 loss in FY 2022) Mar 30
Spectral Medical Inc., Annual General Meeting, Jun 07, 2024 Mar 29
Spectral Medical Inc. Provides Update on the Company's Tigris Trial Mar 01
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients Feb 16
Spectral Medical Inc. Provides Early February Tigris Trial Update Feb 07
Spectral Medical Provides January Tigris Trial Update Jan 30
Spectral Medical Inc. l Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial Jan 10
Spectral Medical Inc. Provides November Tigris Trial Update Dec 05 Spectral Medical Inc. Announces Executive Changes Dec 01
Spectral Medical Inc. Announces Publication of Tigris Trial Methods Paper Nov 17
Third quarter 2023 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in 3Q 2022) Nov 11
Spectral Medical Provides Tigris Trial Update Nov 09
New minor risk - Shareholder dilution Sep 15 Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding Sep 08
New major risk - Financial position Aug 24 Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding from Paradigm Capital Inc. Aug 11
Second quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.011 loss in 2Q 2022) Aug 11
Spectral Medical Inc. Announces Tigris Clinical Trial Update Jul 26
Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors Jun 28
Spectral Medical Inc. Provides Update on Continued Favorable Tigris Clinical Trial Enrollment Jun 21
Spectral Medical Inc. Provides Update on Favorable Tigris Clinical Trial Enrollment May 31
First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.01 loss in 1Q 2022) May 15
Spectral Medical Inc. Announces Resignation of Jim Funk as Director May 06
No longer forecast to breakeven Mar 28
No longer forecast to breakeven Mar 27
Full year 2022 earnings released: CA$0.028 loss per share (vs CA$0.035 loss in FY 2021) Mar 25
Spectral Medical Inc. Provides Update on Tigris Clinical Trial Jan 13
Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.008 loss in 3Q 2021) Nov 16
No longer forecast to breakeven Nov 13
Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.008 loss in 3Q 2021) Nov 11
Forecast to breakeven in 2024 Nov 11 Spectral Medical Inc. announced that it has received CAD 6.8364 million in funding Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding Oct 07
Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding
Second quarter 2022 earnings released: CA$0.011 loss per share (vs CA$0.01 loss in 2Q 2021) Aug 13
Spectral Medical Provides Update on Tigris Clinical Trial Jul 21
US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ for the Treatment of Endotoxemic Septic Shock Jul 12
Spectral Medical Inc. Elects James Funk as Director Jun 22
Spectral Medical Inc. Appoints Sam Amory as Dialco, President May 17
First quarter 2022 earnings released: CA$0.01 loss per share (vs CA$0.007 loss in 1Q 2021) May 14 Shareholder Returns SD4 DE Biotechs DE Market 7D 10.0% 2.1% -0.1% 1Y 9.3% -9.7% 7.4%
See full shareholder returns
Return vs Market: SD4 exceeded the German Market which returned 7.4% over the past year.
Price Volatility Is SD4's price volatile compared to industry and market? SD4 volatility SD4 Average Weekly Movement 11.0% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: SD4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: SD4's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.
Show more Spectral Medical Inc. Fundamentals Summary How do Spectral Medical's earnings and revenue compare to its market cap? SD4 fundamental statistics Market cap €104.49m Earnings (TTM ) -€16.79m Revenue (TTM ) €1.35m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SD4 income statement (TTM ) Revenue CA$2.01m Cost of Revenue CA$1.21m Gross Profit CA$798.00k Other Expenses CA$25.80m Earnings -CA$25.00m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.088 Gross Margin 39.78% Net Profit Margin -1,246.31% Debt/Equity Ratio -41.2%
How did SD4 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/06 20:40 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Spectral Medical Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Dean Cormark Securities Inc. Scott McAuley Paradigm Capital, Inc. Andre Uddin Research Capital Corporation
Show 3 more analysts 
